Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The HIV response is a shared global commitment to equitable health outcomes.
In limited studies to date, semaglutide and other weight-loss drugs appear to be safe and effective for people living with HIV.
Providing a course of antiretrovirals to use after infrequent HIV exposures could lower cost and remove barriers to access.
All participants with detectable HIV on oral meds achieved viral suppression after switching to long-acting injectables.
Certain drugs in this class may increase the likelihood of diabetes and hypertension, but cardiovascular risk factors can be managed.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
Despite progress in some areas, more work is needed to improve health and quality of life.
Drug levels remained adequate throughout pregnancy, so no dose adjustment was needed.
At three years, median height and bone mineral density were similar for children with and without tenofovir exposure in the womb.
Global study highlights the importance of prompt HIV treatment and viral suppression to prevent severe monkeypox.
REPRIEVE trial finds pitavastatin reduced the risk for heart attack, stroke and other major cardiovascular events by 35%.
People with HIV who have an undetectable viral load have zero risk of transmitting the virus to their sex partners.
44% of children treated with two bnAbs maintained viral suppression after stopping antiretrovirals.
Once-daily Biktarvy, long-acting injectable Cabenuva and two-drug combos containing dolutegravir can keep HIV in check for years.
However, those with a very low CD4 count have a substantially shorter life expectancy, emphasizing the need for prompt treatment.
Marc Franke is part of an exclusive circle of people cured of HIV after a stem cell transplant to treat cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.